Industry-leading
Site and Patient Capabilities
Start Studies
with Confidence
In the face of increased cost pressures, longer
development timelines and complex regulatory
requirements, clients need to activate sites, find
and enroll the right patients and start studies
faster. PPD understands the cost implications
that startup delays can have on a trial and
provides fully integrated site and patient
capabilities to accelerate timelines and start
studies with confidence.
Utilizing a comprehensive sites and patients
offering, PPD is able to deliver industry-leading
cycle times to clients and create significant cost
savings while meeting study goals.
18 days
Fas t e r
15 percent
decrease
in startup cycle times
Industry SIA Model*
25 percent
reduction
in mean and median
site activation cycle times
as compared to prior Site Intelligence and Activation (SIA) metrics
Greater predictability using our feasibility
strategy to achieve reduced timelines from final
protocol to site activation
*“SIA model” includes only studies with FP on Jan. 1, 2013 or later to align with full deployment
of new SIA model. Industry benchmark from CMR for the period of 2010-2012.
Activate, Enroll Sites Faster
PPD is able to deliver studies on time with our proven trial optimization methodology.
This four-part approach results in high-level site enrollment and performance and includes:
Development
consulting/early
engagement
Experts with deep
therapeutic knowledge
engage with clients
before the study’s
protocol is developed
or advise on an
existing protocol to
limit amendments and
reduce costs.
Data-driven
analysis
Analytics and expert
recommendations are
used to to improve
forecasting in order
to optimize both the
protocol and the trial
and to mitigate risk
before a study begins.
Investigator
feasibility and site
selection
Continuous
feasibility and
optimization
Sites and investigators
with experience
conducting similar
studies and who are
proven to recruit
patients according
to set timelines
are recommended.
A feedback loop is
used to determine
what parts of the trial
optimization strategy
are successful and
what changes are
needed to create time
and cost savings.
Accurate
Predictability to
Meet Study Timelines
By utilizing Preclarus®, PPD’s innovative data and analytics platform,
project teams are able to provide accurate predictability for site
activation and enrollment in order to meet study timelines. Three
key Preclarus dashboards are used in the startup process:
++ Global site selection: chooses the most qualified sites based on
experience, quality and therapeutic match.
++ Study startup: reports status of country/site selection including
the number of sites identified, eliminated and in the queue to be
activated. Reports from this dashboard can be sent directly to
clients, eliminating the need for additional reporting.
++ Study management: shows an overall picture of study
performance including enrollment projections, status of site
activations and the status of database cleaning.
Empowering Patients
Patients are at the heart of clinical research and their experiences drive
the services we offer our clients. Engaging and empowering clinical
research participants and their caregivers improves retention in studies
and research outcomes. PPD helps its clients deliver life-changing
therapies by continuously expanding its services with a focus on
bringing the trial closer to the patient, through methods including:
++ Piloting the use of wearable technologies to collect data in a more
convenient way for patients
++ Collaborating with patient advocacy groups across different
disease areas to understand patient needs
++ Partnering with leading organizations to bring the trial closer to
the patient in areas such as eConsent and patient enrollment
and retention
++ Coupling patient recruitment via Acurian’s database with sites via
Radiant Research’s network
++ Pioneering a means to pair patients with treatments via the
Melanoma International Collaboration for Adaptive Trials
++ Creating patient and concierge services for engagement in
specialized areas
Confidence Through Partnerships
PPD’s well-established partnerships with targeted networks create a comprehensive approach to site recruitment through
access to high-performing sites. Leveraging these partnerships allows for global strategic site collaborations that offer a
single point of contact, proven site performance and streamlined contracting agreements. PPD’s team of site collaboration
experts creates relationships with external networks and associations and targets high-performing investigators within
large academic teams, co-operative groups and major centers of excellence.
PPD also works closely with Radiant Research, the largest U.S.-based, wholly owned network of clinical trial sites. With
75 Phase I-IV sites nationwide and a database of more than 2.5 million research participants, Radiant has successfully
conducted more than 14,000 multi-therapeutic trials. Radiant’s enrollment rate of 97 percent is significantly better than
industry standard and ranks in the top five percent of clinical trial sites in the U.S.
Rapid Patient
Enrollment
with Acurian
Working with Acurian further strengthens PPD’s
feasibility, patient recruitment and retention offerings
and can be provided as a fully integrated service
offering. Acurian uses proprietary and highly predictive
software analytics to customize the most efficient and
cost-effective approach to recruiting patients for clinical
trials and retaining those patients through to trial
completion. With experience across many therapeutic
areas, Acurian consistently delivers a high rate of return.
1,000,000+
STUDY CANDIDATES REFERRED TO SITES
800+
Enrollment
Projects
7,000
Sites
Engaged
100+
Unique
Indications
5M
Pre-screened
Candidates
70+
Countries
Expedited Payments,
Site Satisfaction
PPD established a dedicated investigator payment team in
order to expedite payments and increase site satisfaction.
The unit has expanded to include 120 team members
located in key global areas including the U.S., U.K., Germany,
Bulgaria, Manila and Singapore. With in-country resources,
team members are able to offer global awareness of
complex regulatory requirements as well as innovative
solutions to associated challenges.
twitter.com/PPDCRO
facebook.com/PPDCRO
youtube.com/PPDCRO
plus.google.com/+PPDCRO
linkedin.com/company/ppd
For more information, please contact us at
+1 877 643 8773, +1 919 456 5600 or at
ppdinfo@ppdi.com.
www.ppdi.com
© 2016 Pharmaceutical Product Development, LLC. All rights reserved.